Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 02:01 ET | Source: Spur Therapeutics

Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress

Spur Therapeutics Presents Updated Phase 1/2 Durability Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress